Microbot Medical Secures FDA Clearance for LIBERTY System, Gains Endorsement

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Feb 24 2026

0mins

MBOT+7.54%

Should l Buy MBOT?

Source: Benzinga

FDA Clearance: Microbot Medical recently achieved FDA 510(k) clearance for its LIBERTY system, designed for precision in peripheral endovascular procedures, marking a significant advancement in medical technology.
Hospital Adoption: The adoption by Tampa General Hospital is seen as a major endorsement of LIBERTY's value, with hospital leadership emphasizing the technology's potential to improve patient care and enhance physician safety, which may drive broader market acceptance.
Market Demand: The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic solution in its category, aimed at addressing the growing demand in the U.S. market, which encompasses approximately 2.5 million procedures annually, indicating a strong market outlook.
Strategic Partnership: Microbot plans to fully launch the LIBERTY system at the Society of Interventional Radiology conference in April 2026, and this strategic partnership is expected to enhance the company's commercial footprint and support market penetration.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MBOT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MBOT

Wall Street analysts forecast MBOT stock price to rise

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.520

Low

5.50

Averages

8.75

High

12.00

Current: 2.520

Low

5.50

Averages

8.75

High

12.00

B. Riley

Buy

initiated

2026-02-10

Reason

B. Riley

Price Target

AI Analysis

2026-02-10

initiated

Buy

Reason

B. Riley initiated coverage of Microbot Medical with a Buy rating and $5 price target. Microbot markets the Liberty Endovascular Robotic System, the first and only single-use, remotely operated robotic platform cleared by the FDA for peripheral vascular procedures, the analyst tells investors in a research note. The firm expects the company to gain commercial traction faster than its robotic peers given its position as the only FDA-cleared system, "clinically validated" benefits including eliminating radiation exposure to operators, and a disposable model that bypasses capital equipment procurement entirely.

Roth Capital

Kyle Bauser

Buy

initiated

$5.50

2025-12-03

Reason

Roth Capital

Kyle Bauser

Price Target

$5.50

2025-12-03

initiated

Buy

Reason

Roth Capital analyst Kyle Bauser initiated coverage of Microbot Medical with a Buy rating and $5.50 price target. The firm says the company's Liberty Endovascular Robotic System achieved FDA clearance in September and has begun commercial use in select U.S. hospitals ahead of a full market release in April 2026. Roth thinks the technology will be useful within procedures that require navigation of complex vascular anatomy while also reducing physical strain and radiation exposure.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MBOT

Unlock Now

About MBOT

Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Microbot Medical to Participate in Oppenheimer Healthcare Conference

1 day agoNewsfilter

First Conference Participation: Microbot Medical will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference from March 16-19, 2026, marking its first invitation, which reflects growing market interest and is expected to enhance the company's visibility in the healthcare sector.
Executive Presentation: CEO Harel Gadot will present live on March 19 at 8:40 am ET, highlighting recent achievements of the LIBERTY system and key market growth drivers, aiming to accelerate customer adoption and increase shareholder value.
Market Release Plans: The LIBERTY system commenced limited market release in late 2025, with plans for a full market launch at the Society of Interventional Radiology (SIR) conference in April 2026, showcasing its unique advantages in peripheral vascular procedures and expected to further drive market adoption.
Strategic Investor Meetings: CFO Rachel Vaknin and VP of Strategic Marketing & Business Development Earl Adamy will meet with institutional investors on March 18, providing opportunities for one-on-one discussions with the management team, aimed at attracting more investor interest in the company's innovative technology and market potential.

Microbot Medical Commends AMA's New Radiation Protection Policy

Mar 04 2026Newsfilter

AMA Policy Adoption: The American Medical Association adopted a new policy in late 2025 to enhance radiation protection for healthcare professionals, emphasizing the need for ongoing research into cumulative radiation effects and the effectiveness of PPE, thereby improving safety standards in the medical field.
LIBERTY System Benefits: Microbot's LIBERTY® Endovascular Robotic System allows remote operation, enabling healthcare providers to work away from radiation sources, with the ACCESS-PVI study demonstrating a 92% relative reduction in radiation exposure, significantly enhancing procedural safety.
Addressing Staffing Shortages: The rising concerns of radiation exposure and staffing shortages in interventional radiology disproportionately affect women, and the LIBERTY system's wireless capabilities reduce reliance on heavy PPE, alleviating musculoskeletal strain and potentially attracting more professionals to the field.
Market Launch Plans: Microbot plans a Full Market Release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to showcase its technological advantages and deepen market adoption, thereby solidifying the company's leadership in endovascular procedures.

Microbot Medical Maintains Stable Operations Amid Geopolitical Tensions

Mar 03 2026stocktwits

Inventory Management: Microbot Medical maintains sufficient inventory of its Liberty system in the U.S. to support current customers while building additional stock to meet anticipated demand, ensuring business continuity and customer satisfaction.
Operational Stability: Despite geopolitical events, Microbot's operations in both the U.S. and Israel remain unaffected, with all personnel operating normally and both internal operations and lead manufacturing partners fully functional, demonstrating the company's resilience.
Market Focus: The company is concentrating its commercial efforts on the U.S. market, managed by its U.S.-based team in Hingham, which ensures uninterrupted service and continued progress in the limited market release of the LIBERTY system.
Stock Market Reaction: Although Microbot's shares traded 3% lower at the time of writing, the stock has risen 76% over the past 12 months, indicating a bullish sentiment among investors regarding the company's future prospects.

Microbot Medical Maintains Operations Amid Geopolitical Events

Mar 03 2026seekingalpha

Stable Operations: Microbot Medical announced that it is not experiencing any business disruptions due to current geopolitical events in the Middle East, ensuring that its headquarters in Massachusetts and R&D operations in Israel remain fully operational, demonstrating resilience in uncertain environments.
Sufficient Inventory: The company disclosed that it has enough inventory in the U.S. to support its current customer base, particularly following the limited market release of the Liberty system in late 2025, ensuring customer demand is met effectively.
Logistics Partnership Enhancement: Microbot is collaborating with its U.S.-based third-party logistics partner to boost inventory in anticipation of increased demand, especially ahead of the planned full market release of the Liberty system in April, showcasing proactive market readiness.
Optimistic Market Outlook: As the full market release of the Liberty system approaches, Microbot Medical's strategic planning and inventory management are expected to position the company favorably in the competitive medical device market, driving future business growth.